The challenges of the journey from target identification through development of a
prophylactic quadrivalent human papillomavirus (HPV) vaccine have been met in Gardasil® …

Human papillomaviruses (HPVs) are one of the most common sexually transmitted
infections and remains a public health problem worldwide. There is strong evidence that …

In 2006, the US Food and Drug Administration (FDA) approved the first vaccine for
prevention of cervical cancer based on the molecular biology of the disease. Gardasil® …

Highlights•Human papillomavirus virus-like particle vaccine development
journey.•Production of VLPs: recombinant protein expression with conformation …

Cervical cancer is an important public health problem worldwide, and especially in
developing countries. The link between cervical cancer and oncogenic human …

Human papillomavirus (HPV) infection is the known cause of almost all cases of cervical
cancer. An understanding of the HPV genome has allowed the development of two …

Cervarix® and Gardasil® are two prophylactic HPV vaccines designed primarily for cervical
cancer prevention. Cervarix is effective against HPV-16,-18,-31,-33 and-45, the five most …

Since the discovery of the causal association between human papillomavirus (HPV) and
cervical cancer, efforts to develop an effective prophylactic vaccine to prevent high-risk HPV …

Human papillomaviruses (HPV) are the causative agents of cervical cancer, the third most
common cancer in women. The development of prophylactic HPV vaccines Gardasil® and …

Objective: TO review the pharmacology, efficacy, safety, tolerability, and
pharmacoeconomics of Cervarix and Gardasil, 2 human papillomavirus (HPV) vaccines …